Therapy Areas: Respiratory
Lyvgen Biopharma enters collaborates with Bristol Myers Squibb for LVGN7409 phase two randomised trial in Combination with Nivolumab
28 November 2022 -

Lyvgen Biopharma, a China-based global biotech company, announced on Sunday that it has entered into collaboration with United States-based Bristol Myers Squibb for an open label, phase two, multicentre, randomised trial of LVGN7409 and docetaxel or nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC).

LVGN7409, a recombinant monoclonal antibody that targets CD40 for activation optimally in tumour microenvironment, which is a member of the tumour necrosis factor (TNF) receptor family (TNFRSF5) and modulates immune responses by activating antigen presenting cells and reprograming the immuno-suppressive tumour microenvironment.

Bristol Myers Squibb's nivolumab is a human monoclonal antibody that binds to the PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response.

LVGN7409 is a recombinant monoclonal antibody that targets CD40 for activation optimally in tumour microenvironment, which is a member of the tumour necrosis factor (TNF) receptor family (TNFRSF5) and modulates immune responses by activating antigen presenting cells and reprograming the immuno-suppressive tumour microenvironment.

Bristol Myers Squibb's nivolumab, a human monoclonal antibody, binds to the PD-1 and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response.

Docetaxel, an anti-tubulin chemotherapy agent, is utilised to treat various types of cancer, including non-small-cell lung cancer, breast cancer, head and neck cancer, stomach cancer, and prostate cancer.

According to the terms of the contract, Lyvgen is to sponsor the study and Bristol Myers Squibb is to provide nivolumab for the combination trial. Lyvgen will have the global commercial and development rights to LVGN7409.

Login
Username:

Password: